bluebird bio Inc. (NASDAQ:BLUE) finished Thursday with a subtraction of -$0.16 to close at $3.38, a downside of -4.52 percent. An average of 5,844,460 shares of common stock have been traded in the last five days. There was a fall of -$0.45 in the past week, and it reached a new high 6 times over the past 12 months. The last 20 days have seen an average of 5,899,030 shares traded, while the 50-day average volume stands at 4,470,754.
BLUE stock has decreased by -7.40% in the last month. The company shares reached their 1-month lowest point of $2.98 on 07/14/23. With the stock rallying to its 52-week high on 01/13/23, shares of the company touched a low of $2.78 and a high of $8.58 in 52 weeks. It has reached a new high 6 times so far this year and lost -51.16% or -$3.54 in price. In spite of this, the price is down -60.61% from the 52-week high.
Insider Transactions
BLUE stock investors should be aware that bluebird bio Inc. (BLUE) stock had its last reported insider trading activity 1 day ago on Aug 10. In this transaction, the insider spent $59,956., Klima Thomas J, disposed of 4,130 shares at a price of $3.50 on Jun 02. The insider now owns more than $14,451 worth of shares. Prior to that, Director Leschly Nick went on to Sale 4,290 shares at $7.80 each on Jan 11. An amount of $33,480 was transacted.
Valuation Metrics
bluebird bio Inc. (BLUE) stock’s beta is 0.92. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 88.77, the price-to-book (PB) ratio at 0.98.
Financial Health
The quick ratio of bluebird bio Inc. for the three months ended June 29 was 3.00, and the current ratio was 3.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. bluebird bio Inc.’s EBITDA margin for the year ending June 29 is -10540.76%. Its gross profit as reported stood at -$6.48 million compared to revenue of $3.6 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, bluebird bio Inc.’s return on assets was -21.00%.
Earnings Surprise
For the three-month period that ended June 29, bluebird bio Inc. had $72.43 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$72.91 million in the quarter, while revenues of $21.24 million were shrunk -37.35%. The analyst consensus anticipated bluebird bio Inc.’s latest quarter earnings to come in at -$0.72 per share, but it turned out to be -$0.67, a 6.90% surprise. For the quarter, EBITDA amounted to -$84.33 million. Shareholders own equity worth $106.95 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at bluebird bio Inc. (BLUE) price momentum. RSI 9-day as of the close on 10 August was 40.10%, suggesting the stock is Neutral, with historical volatility in this time frame at 79.98%.
As of today, BLUE’s price is $3.66 -11.75% or -$0.45 from its 5-day moving average. BLUE is currently trading +2.11% higher than its 20-day SMA and -25.55% lower than its 100-day SMA. However, the stock’s current price level is +2.11% above the SMA50 and -43.48% below the SMA200.
The stochastic %K and %D were 20.72% and 32.03%, respectively, and the average true range (ATR) was 0.42. With the 14-day stochastic at 3.84% and the average true range at 0.38, the RSI (14) stands at 44.01%. The stock has reached -0.13 on the 9-day MACD Oscillator while the 14-day reading was at -0.17.
Analyst Ratings
BofA Securities upgraded bluebird bio Inc. (NASDAQ: BLUE) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for bluebird bio Inc. (BLUE) among analysts is Hold. According to current brokerage recommendations, 2 brokerage firms advise that investors sell BLUE, while 6 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 3 analysts, while 2 others rate it as a “buy”.
What is BLUE’s price target for the next 12 months?
Analysts predict a range of price targets between $3.00 and $11.00, with a median target of $7.00. Taking a look at these predictions, the average price target given by analysts for bluebird bio Inc. (BLUE) stock is $7.27.
